Published in TB and Outbreaks Week, December 24th, 2002
The FDA has selected Focus Technologies to help the organization develop a proactive and comprehensive assessment of antimicrobial resistance. The contract, titled "Surveillance of the Emergence of Antibiotic Resistance," will grant the FDA access to The Surveillance Network (TSN), Focus Technologies' comprehensive, real-time antibiotic resistance database. This access will provide the FDA with unparalleled capabilities to effectively evaluate the development of antimicrobial agents intended to treat patients in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week